74 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism … to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
8-K
EX-1.1
TARS
Tarsus Pharmaceuticals Inc
1 Mar 24
Tarsus Announces Proposed $100.0 Million Public Offering
5:26pm
been furnished with such documents and certificates as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale … if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose
8-K
EX-4.1
TARS
Tarsus Pharmaceuticals Inc
1 Mar 24
Tarsus Announces Proposed $100.0 Million Public Offering
5:26pm
this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder (which shall … and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder
424B5
TARS
Tarsus Pharmaceuticals Inc
1 Mar 24
Prospectus supplement for primary offering
5:17pm
exclude the proceeds, if any, from the exercise of the pre-funded warrants sold in this offering.
The principal purpose of this offering … , and no advertisement, invitation or document relating to the securities may be issued or may be in the possession of any person for the purpose of issue
424B5
32eit1d
29 Feb 24
Prospectus supplement for primary offering
5:08pm
S-3ASR
EX-4.5
o8q5jpsa3
29 Feb 24
Automatic shelf registration
4:32pm
S-3ASR
gvulsoj169 d8
29 Feb 24
Automatic shelf registration
4:32pm
S-8
adv9gkpyyjx0hspe
27 Feb 24
Registration of securities for employees
4:22pm
8-K
EX-1.1
k658gbf97y3a4
2 Aug 23
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of
4:10pm
424B5
ae4m2nfe7tie
2 Aug 23
Prospectus supplement for primary offering
4:08pm